研究等業績 - その他 - 成田 伸太郎
-
佐藤 滋, 齋藤 満, 三浦 嘉子, 沼倉 一幸, 小原 崇, 鶴田 大, 成田 伸太郎, 堀川 洋平, 土谷 順彦, 羽渕 友則, 三浦 昌朋
移植 ( (一社)日本移植学会 ) 44 ( 総会臨時 ) 287 - 287 2009年09月
-
A GENETIC POLYMORPHISM OF THE OSTEOPROTEGERIN GENE IS ASSOCIATED WITH AN INCREASED RISK OF ADVANCED PROSTATE CANCER
Naofumi Narita, Takeshi Yuasa, Norihiko Tsuchiya, Teruaki Kumazawa, Shintaro Narita, Takamitsu Inoue, Zhiyong Ma, Mitsuru Saito, Yohei Horikawa, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 181 ( 4 ) 168 - 168 2009年04月
研究発表要旨（国際会議）
-
EVALUATION OF OUTCOMES AND GENETIC PREDICTIVE FACTORS FOR PROGNOSIS AND TOXICITY IN HORMONE-REFRACTORY PROSTATE CANCER PATIENTS FOLLOWING COMBINATION THERAPY WITH DOCETAXEL, ESTRAMUSTINE, AND CARBOPLATIN
Shintaro Narita, Hiroshi Tsuruta, Mitsuru Saito, Teruaki Kumazawa, Yohei Horikawa, Takeshi Yuasa, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 181 ( 4 ) 293 - 293 2009年04月
研究発表要旨（国際会議）
-
INFLUENCE OF POLYMORPHISMS AND EXPRESSION OF CHROMOGRANIN A AND ENDOTHELIN-1 ON THE DEVELOPMENT AND PROGRESSION OF PROSTATE CANCER
Zhiyong Ma, Norihiko Tsuchiya, Takeshi Yuasa, Shintaro Narita, Yohei Horikawa, Teruaki Kumazawa, Mitsuru Saito, Takashi Obara, Hiroshi Tsuruta, Naoko Kawata, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 181 ( 4 ) 49 - 50 2009年04月
研究発表要旨（国際会議）
-
MICROVASCULAR TUMOR INVASION AS A PROGNOSTIC FACTOR FOR TUMOR RECURRENCE AFTER RADICAL NEPHRECTOMY IN PATIENTS WITH RENAL CELL CARCINOMA
Norihiko Tsuchiya, Takashi Obara, Kojiro Nishio, Teruaki Kumazawa, Shintaro Narita, Yohei Horikawa, Takamitsu Inoue, Mitsuru Saito, Takeshi Yuasa, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 181 ( 4 ) 213 - 214 2009年04月
研究発表要旨（国際会議）
-
OVEREXPRESSION OF BCL-2 SEEN IN RESIDUAL PROSTATE CANCER AFTER NEOADJUVANT CHEMOHORMONAL THERAPY WITH DOCETAXEL FOR LOCALLY ADVANCED PROSTATE CANCER
Teruaki Kumazawa, Hiroshi Tsuruta, Mitsuru Saito, Shintaro Narita, Yohei Horikawa, Takeshi Yuasa, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 181 ( 4 ) 97 - 97 2009年04月
研究発表要旨（国際会議）
-
POLYMORPHISMS OF FIBROBLAST GROWTH FACTOR RECEPTOR 4 HAVE ASSOCIATION WITH THE DEVELOPMENT OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA AND THE PROGRESSION OF PROSTATE CANCER IN A JAPANESE POPULATION
Zhiyong Ma, Norihiko Tsuchiya, Takeshi Yuasa, Shintaro Narita, Yohei Horikawa, Teruaki Kumazawa, Mitsuru Saito, Takashi Obara, Hiroshi Tsuruta, Naoko Kawata, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 181 ( 4 ) 48 - 49 2009年04月
研究発表要旨（国際会議）
-
SIMULTANEOUS LAPAROSCOPIC TREATMENT FOR URETEROPELVIC JUNCTION OBSTRUCTION ACCOMPANIED BY NEPHROLITHIASIS
Norihiko Tsuchiya, Takamitsu Inoue, Takeshi Yuasa, Sohei Kanda, Teruaki Kumazawa, Shintaro Narita, Mitsuru Saito, Hiroshi Tsuruta, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 181 ( 4 ) 736 - 736 2009年04月
研究発表要旨（国際会議）
-
THE NOVEL TUMOR-SUPPRESSOR MEL-18 IN PROSTATE CANCER: ITS FUNCTIONAL POLYMORPHISM, EXPRESSION, AND CLINICAL SIGNIFICANCE
Wei Wang, Takeshi Yuasa, Norihiko Tsuchiya, Zhiyong Ma, Shinya Maita, Teruaki Kumazawa, Shintaro Narita, Takamitsu Inoue, Mitsuru Saito, Hiroshi Tsuruta, Yohei Horikawa, Jian Huang, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 181 ( 4 ) 50 - 50 2009年04月
研究発表要旨（国際会議）
-
移植早期の高齢者レシピエントにおけるタクロリムス(TAC)、セルセプト(MMF)、プレドニゾロン(PDS)の薬物動態
佐藤 滋, 齋藤 満, 鶴田 大, 熊澤 光明, 成田 伸太郎, 堀川 洋平, 湯浅 健, 土谷 順彦, 三浦 昌朋, 加賀谷 英彰, 鈴木 敏夫, 羽渕 友則
日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 ) 100 ( 2 ) 257 - 257 2009年02月
-
Cystoprostatectomy as a treatment of prostate cancer involving the bladder neck.
Teruaki Kumazawa, Norihiko Tsuchiya, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Youhei Horikawa, Takeshi Yuasa, Shigeru Satoh, Tetsuro Kato, Hiroshi Nanjyo, Tomonori Habuchi
Urologia internationalis 83 ( 2 ) 141 - 5 2009年
OBJECTIVE: We evaluated the clinicopathological findings and short- and long-term outcomes of prostate cancer (PCa) patients with bladder neck invasion who underwent cystoprostatectomy. PATIENTS AND METHODS: Between 1989 and 2005, we performed 17 cystoprostatectomies for PCa patients having bladder neck invasion without distant visceral or distant lymph node metastasis. Of the 17 patients, 11 were treated with neoadjuvant hormone therapy and all patients were treated with adjuvant hormone therapy immediately after surgery. RESULTS: All 7 patients in whom pelvic lymph node swelling was identified by preoperative imaging studies had pathological lymph node metastasis. Of the 10 patients judged as cN0 preoperatively, 7 (70.0%) had lymph node metastasis. Although local recurrence was found in 2 (11.8%) patients, no additional urinary diversion or inconvenient urinary symptoms due to PCa progression were observed in any patients. The 5-year prostate-specific antigen recurrence-free survival rate was 62.2%. Cause-specific survival at 5 years after surgery was 87.1%. The 5-year cause-specific survival rate of node-positive patients was 92.3%. CONCLUSION: Cystoprostatectomy followed by immediate hormone therapy may be a feasible treatment option to achieve excellent local control for patients with previously untreated PCa, even in the presence of pelvic lymph node metastasis.
-
APP-029-AM Survivin遺伝子多型が膀胱癌の発症リスクと予後に及ぼす影響についての検討(総会賞応募ポスター,第97回日本泌尿器科学会総会)
河田 真子, 堀川 洋平, 三浦 喜子, 米田 真也, 鶴田 大, 齋藤 満, 井上 高光, 成田 伸太郎, 熊澤 光明, 湯浅 健, 佐藤 滋, 土谷 順彦, 羽渕 友則
日本泌尿器科学会雑誌 ( 一般社団法人 日本泌尿器科学会 ) 100 ( 2 ) 139 - 139 2009年
-
APP-050-AM 前立腺癌におけるchromogranin Aならびにendothelin-1の臨床的意義(総会賞応募ポスター,第97回日本泌尿器科学会総会)
馬 智勇, 土谷 順彦, 湯浅 健, 成田 伸太郎, 堀川 洋平, 熊澤 光明, 鶴田 大, 齋藤 満, 河田 真子, 井上 高光, 佐藤 滋, 小川 修, 羽渕 友則
日本泌尿器科学会雑誌 ( 一般社団法人 日本泌尿器科学会 ) 100 ( 2 ) 149 - 149 2009年
-
Laparoscopic Versus Retroperitoneoscopic Living Donor Nephrectomy: Comparison of Two Procedures Regarding Clinical Outcome and Complication Rate
Mitsuru Saito, Norihiko Tsuchiya, Shintaro Narita, Hiroshi Tsuruta, Takashi Obara, Takamitsu Inoue, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi
AMERICAN JOURNAL OF TRANSPLANTATION ( WILEY-BLACKWELL PUBLISHING, INC ) 9 441 - 441 2009年
研究発表要旨（国際会議）
-
Transplantation into the Long-Term Defunctionalized Bladder: Is It Cause of Vesicoureteral Reflux to the Renal Graft?
Takamitsu Inoue, Mitsuru Saito, Shigeru Satoh, Yoshiko Miura, Teruaki Kumazawa, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habuchi
AMERICAN JOURNAL OF TRANSPLANTATION ( WILEY-BLACKWELL PUBLISHING, INC ) 9 520 - 521 2009年
研究発表要旨（国際会議）
-
Where Is the Most Preferable Surgical Wound Site for Living Donor Nephrectomy? A Questionnaire Assessment
Mitsuru Saito, Norihiko Tsuchiya, Shinya Maita, Hiroshi Tsuruta, Takashi Obara, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi
AMERICAN JOURNAL OF TRANSPLANTATION ( WILEY-BLACKWELL PUBLISHING, INC ) 9 440 - 441 2009年
研究発表要旨（国際会議）
-
Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.
Norihiko Tsuchiya, Takamitsu Inoue, Shintaro Narita, Teruaki Kumazawa, Mitsuru Saito, Takashi Obara, Hiroshi Tsuruta, Yohei Horikawa, Takeshi Yuasa, Shigeru Satoh, Tomonori Habuchi
The Journal of urology 180 ( 6 ) 2389 - 95 2008年12月
PURPOSE: There is considerable interindividual diversity in the development of adverse reactions during chemotherapy for cancers. This diversity is suggested to be attributable to differences in the disposition of chemotherapeutic agents, which is modified by genetic polymorphisms. In this study we evaluated the possible association of polymorphisms of genes involved in the metabolism, detoxification and transport of the agents with adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin therapy. MATERIALS AND METHODS: A total of 40 patients with urothelial cancer who received methotrexate, vinblastine, doxorubicin and cisplatin or high dose methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy between 1996 and 2005 at Akita University Medical Center were included in this study. Four genetic polymorphisms (ABCB1, GSTP1, CYP3A5 and MTHFR) and clinical parameters were included in the analysis to determine whether there was any association with the grade of adverse reactions at the first cycle and the worst grade of each adverse reaction throughout the chemotherapy period. RESULTS: On multivariate analysis the CYP3A5 A6986G genotype *3/*3 (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for leukocytopenia (grade 3 or greater) throughout the period of chemotherapy. The mean white blood cell count nadir in patients with genotype *3/*3 was significantly lower than that in those with the *1 allele (1,542 +/- 903 vs 2,431 +/- 973/mm(3), p = 0.009). CONCLUSIONS: The A6986G polymorphism of CYP3A5, which is involved in the metabolism of vinblastine and doxorubicin, might be a genetic predictor of the severity of leukocytopenia induced by chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin.
-
Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Zhiyong Ma, Norihiko Tsuchiya, Takeshi Yuasa, Takamitsu Inoue, Teruaki Kumazawa, Shintaro Narita, Yohei Horikawa, Hiroshi Tsuruta, Takashi Obara, Mitsuru Saito, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
International journal of cancer 123 ( 11 ) 2574 - 9 2008年12月
Fibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand-induced tyrosine kinase activity. The Glycine (Gly) to Arginine (Arg) polymorphism at codon 388 (Gly388Arg), which encodes an amino acid in the transmembrane part of the FGFR4 gene, was reported to be associated with an increased risk in some carcinomas. We investigated the association between the Gly388Arg polymorphism or the G or A polymorphism at intron 11 (rs2011077) of FGFR4, which was located 1,213 base pairs apart from the Gly388Arg polymorphism, and the risk of prostate cancer or benign prostate hyperplasia (BPH), and the prostate cancer disease status in Japanese men. Genotypes of Gly388Arg and rs2011077 polymorphisms of FGFR4 were determined in 492 patients with prostate cancer, 165 patients with BPH and 179 male controls. Regarding the Gly388Arg polymorphism, individuals with the ArgArg genotype had a 2.207- and 1.958-fold increased risk of prostate cancer and BPH, and a 1.804-fold increased risk of metastatic prostate cancer compared with those with the GlyGly genotype. Regarding the rs2011077 polymorphism, individuals with the GG genotype had a 6.260- and 3.033-fold increased risk of prostate cancer and BPH, and a 5.550-fold increased risk of metastatic prostate cancer compared with those with the AA genotype. Our results indicate that the FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of prostate cancer and BPH, and the progression of prostate cancer in a Japanese population.
-
Characterization of prostate cancer detected at repeat biopsy.
Takeshi Yuasa, Norihiko Tsuchiya, Teruaki Kumazawa, Takamitsu Inoue, Shintaro Narita, Mitsuru Saito, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi
BMC urology 8 14 - 14 2008年11月
BACKGROUND: The aim of this study was to investigate the characteristics of prostate cancer patients who were diagnosed at repeat biopsy and compare them to non-cancerous patients or patients who were diagnosed at initial biopsy. METHODS: We carried out a retrospective analysis of clinical and pathological data from 576 patients, which included data on the period of time from radical prostatectomy to biochemical failure. RESULTS: Cancer was diagnosed in 191 (33%) of 576 patients at initial biopsy and in 23 (18%) of 127 patients who underwent a repeat biopsy. Cut-off values of 0.80 and 0.30 for prostate specific antigen velocity (PSAV) and prostate specific antigen density (PSAD), respectively, were determined using ROC curve analysis. Based on these values, PSAV and PSAD were able to predict 94% (46 of 49) of negative repeat biopsies, indicating that these patients had undergone unnecessary repeat biopsies. Although the patients who were diagnosed at repeat biopsy had a higher rate of organ-confined tumor than those who were diagnosed at initial biopsy (73% and 44%, respectively; P = 0.041), there were no differences in the recurrence rate or the duration of biochemical failure-free survival between the two groups. CONCLUSION: PSAV and PSAD may be useful indicators of the results of repeat biopsies. Although prostate cancer that was diagnosed at repeat biopsy was associated with a more favorable pathological profile, it was not associated with a better outcome after radical prostatectomy.